Patent 8084582 was granted and assigned to Xencor on December, 2011 by the United States Patent and Trademark Office.
The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.